Morgan Stanley upgrades Delek US stock rating to Equalweight on EPA exemptions

Delek US (DK) has seen significant analyst upgrades, with Morgan Stanley raising its rating from Underweight to Equalweight and its price target to $34.00 from $19.00, and Wolfe Research upgrading to Outperform with a $40.00 target. This reassessment is primarily driven by the EPA's decision to grant small refinery exemptions, which Morgan Stanley estimates could be worth $400 million ($6.50 per share) for 2023/2024 and $200 million annually through 2028, substantially improving Delek's financial outlook. The positive regulatory news, combined with a Q2 2025 earnings beat (adjusted EPS of -$0.56 vs. -$0.86 forecast and revenue of $2.76 billion vs. $2.67 billion forecast), has contributed to the stock's 157% surge over the past six months.

Analysis

Delek US (DK) has experienced a significant positive shift in its investment profile, primarily driven by a favorable regulatory development. The U.S. Environmental Protection Agency's decision to grant small refinery exemptions (SREs) is a material catalyst, with Morgan Stanley estimating a one-time benefit of approximately $400 million ($6.50 per share) for the 2023/2024 period and a recurring annual value of about $200 million through 2028. This outlook is corroborated by TD Cowen, which projects a minimum of $150 million in additional annual EBITDA from the exemptions. This regulatory tailwind has prompted multiple analyst upgrades, including Morgan Stanley's rating change to Equalweight with a price target nearly doubled to $34.00, and Wolfe Research's upgrade to Outperform with a $40.00 target. The improved outlook is further substantiated by Delek's recent Q2 2025 financial performance, which featured a narrower-than-expected loss with an adjusted EPS of -$0.56 against a -$0.86 forecast, and revenues of $2.76 billion that beat estimates. The market has reacted strongly to these developments, with the stock surging 157% over the past six months.

Key Decisions for Investors

• Investors with bearish or underweight positions on Delek US should re-evaluate their thesis, as the EPA's small refinery exemptions create a significant, multi-year financial tailwind that fundamentally improves the company's earnings and cash flow outlook.
• While the analyst upgrades and earnings beat are positive, investors should consider that the stock's 157% rally in the past six months may have already priced in much of this news, warranting a careful evaluation of the entry point relative to the new price targets of $34 to $40.
• Future performance will depend on the realization of these regulatory benefits; investors should monitor upcoming quarterly reports to confirm that the estimated $150-$200 million annual contribution from exemptions translates into tangible EBITDA growth and sustained earnings beats.